The company covers an area of134,398 square meters, with a production workshop of 43,200 square meters conforming to the national good manufacturing practice (GMP for short) and a green area of 12000 square meters. The production lines of capsules, tablets, syrups, small-volume injections and freeze-dried powder injections owned by the company have passed the national GMP certification, and all production lines have reached the domestic advanced level.
In 20 10, the company realized industrial output value of 2 billion yuan, sales income of1467 million yuan, and paid taxes for the country of 298 million yuan. Since the restructuring in 2000, the company has paid a total of 654.38+32.2 million yuan in tax revenue, which has made remarkable achievements and become a pillar industry of local economic development and an important source of local fiscal revenue in Guizhou.
In the process of development, the company has been committed to improving corporate governance and constantly improving the level of corporate governance. The company has formulated the standard articles of association and the rules of procedure of the "Three Meetings", implemented the independent director system, set up the strategic development committee, the audit committee, the nomination committee and the remuneration and assessment committee, formulated a strict and standardized financial system and information disclosure system, and formed a set of management mechanism with clear rights and responsibilities and checks and balances of power, which provided institutional guarantee for the company's sustained and healthy development.
The company has more than 5,200 employees, 78% of whom are college graduates or above. In line with the concept of "educating people for a hundred years", the company has established a systematic training system to comprehensively improve the quality of employees.
In March 2004, the company used120,000 study funds to jointly run a school with Antai School of Management of Shanghai Jiaotong University, and established Guiyang Class of Antai School of Management of Shanghai Jiaotong University. 50 middle-level management cadres of the company have become EMBA students in this class, which is the successor force of the company's development. The company also sent professional and technical personnel to relevant pharmaceutical colleges for professional training, focusing on improving the company's technical strength and cultivating innovative spirit; Adhere to the staff training system, and constantly strengthen the improvement of staff cultural quality, self-cultivation and technical skills. The employees of the whole company are trained in strict accordance with more than 300 hours a year.
In the economic crisis in 2008, Baiyi not only failed to reduce production and lay off employees, but also expanded employment and absorbed social labor, making due contributions to social stability and development.
At present, the company's main products are Aidi injection, Yinxingdamo injection (Xingding injection), compound Mylabris capsule (Kangsaidi capsule), Keke capsule, cold cough syrup, Shugan Yiyang capsule, Jingulian capsule and Luobo injection. , and formed a series of products with enterprise advantages. Among them, Aidi Injection and Compound Mylabris Capsule (Kangsaidi Capsule) are new biphasic anti-tumor drugs, and the research of Aidi Injection, a compound traditional Chinese medicine injection, has reached the gene level. The fourth generation Ginkgo biloba preparation-Yinxingdamo injection (Xingding injection) is an effective drug for treating cardiovascular and cerebrovascular diseases and peripheral circulation disorders, and its development and production have injected new vitality into the company. Lobplatin injection is the third generation platinum antineoplastic drug in tumor chemotherapy. Compared with other platinum anti-tumor drugs, it has the advantages of no nephrotoxicity, ototoxicity and neurotoxicity, and has no cross-resistance with other platinum drugs.
For a long time, the company has always attached great importance to the promotion of technological innovation and scientific research and development to enterprises, emphasizing that "technology is the driving force for the company's progress." In 2005, the company won the title of "National Excellent Private Technological Innovation Enterprise". In 2006, the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Finance, the General Administration of Customs and State Taxation Administration of The People's Republic of China awarded our company the "National Certified Enterprise Technology Center". The center has made some achievements in the research and development and production of new products such as traditional Chinese medicine injections and oral liquid preparations, and new solid preparations such as orally disintegrating tablets, effervescent tablets and sustained and controlled release preparations, and has great advantages in the industry. In 2006, the company was approved by the Ministry of Personnel as an enterprise postdoctoral workstation. In 2007, with the approval of the Science and Technology Department of Guizhou Province, our company was established as the engineering technology research center of new drug release system in Guizhou Province. In 2008, it was approved as a national innovative pilot enterprise, and was also rated as a high-tech enterprise in Guizhou Province in the same year. In 2008, with the approval of the Development and Reform Commission of Guizhou Province, our company also obtained the Engineering and Technology Center for New Preparations of Ethnic Medicine in Guizhou Province, and obtained the financial and technical support from the state. In 2009, the company was approved as a national innovative enterprise. In the same year, it was awarded the "National and Local Joint Engineering Technology Research Center for New Preparations of Southwest Ethnic Medicine" by the National Development and Reform Commission. On this basis, our company is actively strengthening product research and development, and is carrying out many projects in an orderly way in new product development and dosage form modification. At present, the company is studying the variety ***4 1 one, including 3 cardiovascular and cerebrovascular diseases 13, 4 anti-tumor diseases and 9 cold and cough diseases. Six new Chinese medicine drugs developed by the company have entered the third clinical stage, which will become the new profit growth point of the company in the future and inject new vitality into the company. Among them, Compound Polygonum Cuspidatum Dropping Pills and Miyixinle Dropping Pills have great market potential.
The company has always attached great importance to the protection of intellectual property. In 2004, a special intellectual property department was established, and measures such as applying for patent protection and creating well-known trademarks were taken to develop core technologies and enhance the independent innovation ability of enterprises. The company has applied for 229 patents and granted 1 12 patents, including 9 patents for invention and 2 patents for design. 202 trademarks were applied for and obtained 183. Three major trademarks, Baiyi, Zuozubaiyi and Tangke, are registered in Madrid, and trademarks are registered in 26 countries. "Baiyi" and "Coco Keke" are well-known trademarks in China, while "Zuozu Baiyi" is a well-known trademark in Guizhou. Aidi Injection, the core product with independent intellectual property rights, won the 10th National Patent Excellence Award in 2008. Guizhou Baiyi Pharmaceutical was listed as the first batch of enterprises with intellectual property advantages in Guizhou Province and the fourth batch of intellectual property pilot units in China. The number of patent applications and trademark applications ranks first in the same industry in the province and first in the same industry in the country.
Following the successful acquisition of Guilin Lijiang Pharmaceutical and Yunnan Nanzhao Pharmaceutical, it also successfully acquired Guizhou Ethnic Pharmaceutical. Starting from this year, we will implement the collectivization operation mode and optimize enterprise management.
Under the leadership and care of all levels in Guizhou province and city, "Guizhou Miao Medicine Group" was established. The company controls Miao medicine group by injecting capital into the company brand and network; Assets and/or products of other enterprises are invested in enterprises. On September 20 10, the company recruited the first batch of Miao medicine graduate students in conjunction with Beijing University of Chinese Medicine as the talent resource reserve of Miao medicine group. The establishment of Miao Medicine Group, aiming at the characteristics of traditional Chinese medicine and ethnic medicine industry in Guizhou, greatly promoted the position of Miao medicine in China pharmaceutical industry and promoted the development of local medicine and Miao medicine enterprises in Guizhou.
Baiyi Pharmaceutical has been committed to public welfare undertakings. In the freezing disaster in early 2008, Bai Yi immediately sent a message of condolences to the people in the disaster area and donated 600,000 yuan to support the disaster area. In the Wenchuan earthquake in Sichuan in May 2008, we rushed to the forefront and donated cash 1.24 million yuan and medicine value1. At the beginning of this year, Guizhou suffered from drought and donated 2.8 million yuan in cash; And establish Hope Primary School in Hezhang County, a national poverty-stricken county.
With the mission of "excellent medical product provider and health service leader", the company adheres to the values of "health 100, quality 100, gratitude 100, innovation 100" in the tide of economic market, providing customers with high-quality and efficient products that meet environmental protection requirements and creating for investors. "To become a respected company with sustainable management potential in China pharmaceutical industry". Located at No.220-1Baiyun Avenue, Guiyang City, 8 kilometers away from Guiyang City. Covering area 134398 m2.